P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease

Alzheimer’s disease (AD) is characterised by a long preclinical phase. Although phosphorylated tau (p‐tau) species such as p‐tau217 and p‐tau231 provide accurate detection of early pathological changes, other biomarkers capable of staging disease progression during preclinical AD are still needed. C...

Descripción completa

Detalles Bibliográficos
Autores principales: Lantero‐Rodriguez, Juan, Snellman, Anniina, Benedet, Andrea L, Milà‐Alomà, Marta, Camporesi, Elena, Montoliu‐Gaya, Laia, Ashton, Nicholas J, Vrillon, Agathe, Karikari, Thomas K, Gispert, Juan Domingo, Salvadó, Gemma, Shekari, Mahnaz, Toomey, Christina E, Lashley, Tammaryn L, Zetterberg, Henrik, Suárez‐Calvet, Marc, Brinkmalm, Gunnar, Rosa Neto, Pedro, Blennow, Kaj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649868/
https://www.ncbi.nlm.nih.gov/pubmed/34725927
http://dx.doi.org/10.15252/emmm.202115098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649868/
https://www.ncbi.nlm.nih.gov/pubmed/34725927
http://dx.doi.org/10.15252/emmm.202115098

Ejemplares similares